Announcements Trials
Browse Landscape

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 2

Sponsor

Cancer Type

Other hematologic neoplasm 5Myeloid 4Lymphoid 4Plasma cell 2Other solid neoplasm 2Gynecologic 2Gastrointestinal 2Thoracic 1Sarcoma 1Genitourinary 1Dermatologic 1CNS 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Solid Tumor 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Mesothelioma, Malignant 1Mesothelioma 1Kidney Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 77Injections 67Carboplatin 38Nivolumab 31Pemetrexed 29Cisplatin 29Cyclophosphamide 25Specimen Handling 24Interviews as Topic 24tislelizumab 20atezolizumab 20Bevacizumab 20Paclitaxel 19fludarabine 16Standard of Care 16Practice Guidelines as Topic 16Docetaxel 16Ipilimumab 15toripalimab 14Educational Status 14Cetuximab 14Fluorouracil 13Oxaliplatin 12Etoposide 12olaparib 11durvalumab 11Methods 11Gemcitabine 11Early Intervention, Educational 11Drug Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Blood Component Removal × Other solid neoplasm × 1 year × Clear all
NCT04981119 2026-06-02

BASECAMP-1

A2 Biotherapeutics Inc.

Recruiting
200 enrolled
BreastGastrointestinalGenitourinaryGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Kidney Neoplasms, Mesothelioma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT07137312 2025-12-23

Ex Vivo Expansion (ACT-X)

Mayo Clinic

Recruiting
24 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡